



MICROVENTION LAUNCHES ENDOVASCULAR TECHNOLOGY IN CHINA FOR THE TREATMENT OF CEREBRAL AND PERIPHERAL VASCULAR DISEASES

Chinese Regulatory Approval Paves Way for Sales via Distribution Partner

ALISO VIEJO, CA, July 12, 2005 -- Microvention, Inc., a leading developer, manufacturer and marketer of minimally invasive treatments for cerebral and peripheral vascular diseases, announced today that it has received regulatory approval from the People's Republic of China State Food and Drug Administration (SFDA) to sell its HydroCoil® Embolic System (HydroCoil System) and MicroPlex® Coil System (MicroPlex System) throughout China. The medical devices will be sold through Microvention's Chinese distributor, Beijing Aidefan Medical Device Ltd., headquartered in Beijing, China.

Mike Kleine, President and CEO of Microvention, said that these therapeutic devices are now being sold and used in nearly 30 countries throughout the world.

"The medical device registration certificates received from the SFDA for both the HydroCoil and MicroPlex Systems represent another important regulatory milestone for Microvention," said Kleine. "Clearing this hurdle provides us the opportunity to reach thousands of patients in China with our technology - a less-invasive treatment for cerebral aneurysms. With the capability to market our family of products through a top distribution partner in China, we are confident that we will rapidly expand our presence in this key international market."

The HydroCoil System is designed to be a more durable solution for endovascular occlusion of aneurysms and other vascular lesions. It is a unique embolization device combining the Company's platinum microcoil technology with a highly expandable microporous hydrogel called Intelligel™, a responsive or "smart material" that expands to a predetermined diameter after several minutes. The superior volume filling of the Hydrocoil System provides enhanced occlusion for vascular lesions compared to bare platinum coils. Physicians have the ability to precisely control delivery of the device which can be repositioned if necessary. The HydroCoil System combines the safety and ease-of-use of platinum coils with the filling and healing properties of the hydrogel.

The MicroPlex System is a complete line of platinum coils for the treatment of cerebral aneurysms and other vascular lesions. The system incorporates a wide range of three dimensional framing coils, multiple sizes and configurations of helical filling coils and a unique soft finishing coil for placement in the remaining spaces. These coils are designed to work both independently and in conjunction with the HydroCoil System to occlude vascular lesions efficiently and effectively. Microvention's embolic coils offer a durable endovascular therapeutic alternative to neurosurgical clipping in the treatment of cerebral aneurysms, as well as an effective device for embolization of vascular lesions in the periphery.

About Microvention, Inc.

Microvention, Inc. (www.microvention.com) is a privately held medical-device company dedicated to the development and commercialization of new catheter-based technologies for the endovascular treatment of peripheral and cerebral vascular diseases. The company has received 510(k) clearance and CE Mark for both its MicroPlex Coil System and the HydroCoil Embolization System to treat cerebral aneurysms. Microvention sells its products through its direct sales force in the U.S., Canada, France, Germany and the United Kingdom and through distributors in various other countries.

Microvention Contacts:

Michael Kleine, President, CEO
William Hughes, Vice President, CFO
Ph. 949-461-3314
Fx. 949-461-3329

Matt Clawson (Media)
Allen & Caron, Inc.
Ph. 949-474-4300
Fx. 949-474-4330